Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00438581
Status:
UNKNOWN
Last Update Posted:
2007-02-27
First Post:
2007-02-20
Brief Title:
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed Refractory or Transformed Non-Hodgkins Lymphoma
Sponsor:
McGill University
Organization:
McGill University
Study Overview
Official Title:
Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan Zevalin With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed Refractory or Transformed Non-Hodgkins Lymphoma
Status:
UNKNOWN
Status Verified Date:
2007-02
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Zevalin
Brief Summary:
This aim of this study to evaluate the safety and efficacy of combining a single course of Yttrium 90 Ibritumomab Tiuxetan a radiolabeled monoclonal antibody Zevalin with high-dose BEAM chemotherapy and autologous peripheral stem cell transplantation in patients with relapsed refractory or transformed Non-Hodgkins lymphoma
Detailed Description:
Relapse rates after chemotherapy for relapsed refractory or transformed Non-Hodgkins lymphoma NHLremain very high NHL is a radiosensitive tumor We hypothesize that targeted radioimmunotherapy combined with high-dose chemotherapy may increase response and survival rates in a safe and reliable manner
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None